Euromec

Quick links to important sections

Euromec

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Euromec

Quick Facts

Property Description
Active Ingredient (INN) Ivermectin
Typical Form Oral tablet (for systemic use)
Pharmacological Class Anthelmintic; Macrocyclic Lactone
General Purpose Neutralizing parasitic activity
Origin/Type Semi-synthetic compound (derived from Streptomyces avermitilis)

Euromec is a medicinal product based on the active ingredient Ivermectin, primarily used as an anti-parasitic drug to combat infections caused by various parasitic organisms. It is a vital, broad-spectrum medication that is globally recognized for its high efficacy against numerous parasitic threats.


What Type of Medicine is Euromec? Classification and Origin

Euromec, containing Ivermectin, is classified as an anthelmintic and anti-parasitic drug, belonging to the distinct macrocyclic lactone class of compounds. This class is structurally and chemically unique among the agents used to treat parasitic worms (helminths) and external parasites.

The active ingredient, Ivermectin, is a semi-synthetic compound derived from avermectins, which are substances originally isolated from the fermentation products of the soil bacterium Streptomyces avermitilis. This compound is recognized as an endectocide, meaning it is effective against both internal parasitic worms and certain external parasites. For patient use, Euromec is typically formulated as a single-ingredient product presented as an oral tablet for internal administration.


General Purpose: How Euromec Works Against Parasites

The overall purpose of Euromec is to clear the parasitic burden within the human host by directly disrupting the organism’s vital functions. This action is highly selective, targeting the parasite's nervous system without readily affecting the host.

Ivermectin acts by binding to specific glutamate-gated chloride ion channels found in the nerve and muscle cells of the parasites. This binding causes the rapid and effective paralysis of the organisms. This selective mechanism is supported by pharmacological studies, ensuring the drug is targeted to address the parasitic threat while being generally well-tolerated in humans. By immobilizing the parasites, the medication allows the body’s natural processes to remove the now-inactivated organisms.

What side effects are possible with Euromec?

Euromec’s (Ivermectin) safety profile is officially characterized by frequency classifications and System-Organ Class (SOC) groupings, detailing the possible adverse reactions reported in regulatory documents.

Adverse Reactions and Frequencies

The frequency of side effects is often related to the extent of the parasitic infection being treated. Reactions are classified based on regulatory definitions:

  • Common: Adverse effects reported in ge 1/100 people, which may include pruritus (itching), headache, musculoskeletal pain (myalgia, arthralgia), pyrexia (fever), rash, and dizziness.
  • System-Organ Classes: Reactions are formally grouped into categories such as Nervous System Disorders, Gastrointestinal Disorders, Skin and Subcutaneous Tissue Disorders, and Blood and Lymphatic System Disorders.

Serious Adverse Reactions and Safety Considerations

The official labeling documents highlight risks of Serious Adverse Reactions (SARs) that are critical but rare. These include post-marketing reports of Toxic Epidermal Necrolysis (TEN) and Stevens-Johnson Syndrome (SJS), which are severe skin reactions. Neurological events, including encephalopathy and coma, have been reported as serious toxicity.

Population-Specific Notes: Safety documents note that the severity of adverse reactions may be increased in patients with a high Loa loa microfilarial burden. Use is also restricted in children weighing less than 15 kg due to insufficient safety data. Adverse reactions are frequently observed during the first 3 days post-treatment and are often linked to the extent of the parasitic infection.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented manifestations and required emergency actions for an overdose of Euromec (Ivermectin), based strictly on government regulatory information.

Overexposure may affect the central nervous system, gastrointestinal system, and cardiovascular system. Documented manifestations from regulatory sources include confusion, severe sleepiness (somnolence), loss of coordination (ataxia), tremors, nausea, vomiting, diarrhea, dizziness, headache, and low blood pressure (hypotension).

Severe Outcomes and Emergency Actions

Outcome Immediate Action Required
Seizures, Coma, Death Call emergency services immediately (911/equivalent).
Collapse or Trouble Breathing Seek immediate medical attention or contact the Poison Help line.

The regulatory guidance mandates seeking immediate medical attention if an overdose is suspected. Specifically, emergency services must be called immediately if the affected individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

There is no specific antidote identified in the official labeling for Ivermectin overdose. Management is entirely supportive and symptomatic, focused on maintaining vital functions. Gastric decontamination, potentially with activated charcoal, may be considered in cases of significant ingestion, as described in regulatory summaries.

Therapeutic Uses of Euromec

Quick Facts

  • Main Uses: May help manage pain associated with certain types of arthritis.
  • Common Use: May provide temporary relief of mild to moderate pain.
  • Therapeutic Domain: Conditions involving joint and muscle discomfort.

Euromec is a prescription medication utilized in a therapeutic regimen to address discomfort and inflammation. It is primarily indicated for assisting patients in the management of pain and swelling related to inflammatory conditions of the joints, such as rheumatoid arthritis and osteoarthritis. Its use may facilitate an improved quality of life and functionality in daily activities for individuals experiencing these conditions.

The medication is frequently incorporated into treatment plans for the short-term relief of pain affecting the muscles and skeletal system. It functions as a nonsteroidal anti-inflammatory drug (NSAID), aiming to modulate the body’s response to pain signals. This therapeutic effect contributes to the potential alleviation of discomfort in affected areas.

For a comprehensive understanding of the indications, proper use, and safety profile of this medication, patients are advised to consult a healthcare professional.

Eligibility and Restrictions for Use

Who Can and Cannot Use Euromec?

This section outlines the officially documented population eligibility rules for Euromec (Ivermectin), strictly based on governmental regulatory labeling.


Contraindications and Absolute Restrictions

Euromec is contraindicated and must not be used in patients with a known history of hypersensitivity to the active substance, Ivermectin, or to any component of the product formulation. Furthermore, the medicine should not be used during pregnancy because its safety in pregnant women has not been established by regulatory authorities.


Population Eligibility Rules

Classification Regulatory Statement of Eligibility
Pediatric Use Safety and effectiveness have not been established in children weighing less than 15 kilograms (kg).
Geriatric Use Treatment requires caution, reflecting the greater frequency of decreased hepatic, renal, or cardiac function in older adults.
Lactation Status Treatment of nursing mothers is restricted and should only be undertaken when the benefit to the mother outweighs the possible risk to the newborn.
Co-endemic Disease Patients from Loa loa-endemic areas require pretreatment assessment and careful follow-up due to the risk of serious neurological events.

These eligibility rules define the established safety boundaries for Euromec and mandate conditional use for specific populations based on official regulatory classifications.

What should I know about interactions with other medicines?

Euromec (which contains the active ingredient ivermectin) can interact with a variety of other medicines and products. It is crucial to inform your doctor or pharmacist of all medications, over-the-counter drugs, vitamins, herbal products, and supplements you are currently taking before starting Euromec treatment.

️ Potential Drug-Drug Interactions

Co-administration of ivermectin with certain drugs can increase the concentration of ivermectin in the body, potentially increasing the risk of side effects. Conversely, some drugs may decrease its effectiveness. Of particular importance are drug-drug interactions that are considered moderate or major in severity.

  • Blood Thinners (Anticoagulants): Ivermectin may potentiate the effects of anticoagulants such as warfarin. This combination can increase the risk of bleeding, and close monitoring of coagulation parameters may be necessary.
  • CYP3A4 Inhibitors: Medications that inhibit the CYP3A4 enzyme, such as certain antifungals (e.g., ketoconazole, itraconazole, posaconazole) and some HIV/AIDS medications (e.g., ritonavir), can slow the breakdown of ivermectin, leading to increased levels of the drug in the body and a higher risk of adverse effects.
  • Other CNS Depressants: Although not commonly reported, taking ivermectin with other medications that cause central nervous system (CNS) depression (e.g., sedatives or certain anxiety medicines) could potentially enhance side effects such as drowsiness and dizziness. Alcohol may also increase the risk of CNS side effects.

Other Interactions

Euromec should be taken on an empty stomach with water, as food can increase the absorption of ivermectin. Consult your healthcare provider for personalized advice regarding all potential interactions.

Mechanism of Action

How Euromec Works

Euromec's active ingredient, Ivermectin, exerts its pharmacodynamic action by influencing key mechanistic domains within susceptible invertebrate parasites. The primary mechanism involves selective interaction with glutamate-gated chloride ion channels present in the nerve and muscle cells of these organisms.

Binding to these channels increases the permeability of the cell membrane to chloride ions. This molecular step causes an influx of chloride, resulting in the hyperpolarization of the parasitic nerve and muscle cell membranes, which fundamentally reduces their electrical excitability.

The downstream cascade of widespread cellular hyperpolarization is the induction of neuromuscular blockage. This critical pathway effect manifests as paralysis of the parasite, compromising its ability to move and feed. The resulting system-level physiological consequence is the systemic physiological disruption of essential parasite functions.

Dosage and Administration Information

How to Use Euromec (Ivermectin)

The usage of Euromec is governed by specific instructions focusing on proper administration, dose calculation, and timing.


Administration and Dosage Rules

Euromec tablets are administered via the oral route for systemic use against parasitic infections. Dosing is primarily weight-based, meaning the quantity of medication is calculated according to the patient's body weight, typically at 150–200 mcg/kg of body mass, to determine the total number of 3 mg tablets. This calculation provides a precise, standardized dose that should be taken in one instance.

Field Instruction
Route of administration Oral, for systemic treatment.
Dosing schedule Typically a single oral dose calculated by body weight.
Timing in relation to meals Must be taken on an empty stomach, generally meaning two hours before or after eating, to maximize absorption.

Frequency and Special Conditions

For many indications, such as Strongyloidiasis, Euromec is used as a single, curative dose. For other persistent parasitic conditions like Onchocerciasis, the drug follows an intermittent schedule, requiring redosing every 3 to 12 months for long-term control.

Pediatric administration is constrained by weight; the medication is not recommended for children weighing less than 15 kilograms. For very young patients, the tablets may be crushed prior to intake to facilitate swallowing. Since the standard regimen is a single dose, the concept of a missed daily dose does not apply. If a scheduled intermittent dose is missed, it is generally recommended to take the dose as soon as it is remembered to maintain the treatment program.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Euromec

Evidence for Use in Intestinal Strongyloidiasis

Research has explored the medicine's role in intestinal strongyloidiasis, an infection caused by the parasitic roundworm Strongyloides stercoralis. Research involved Randomized Controlled Trials (RCTs) and comparative studies that were evaluated in populations of adults and older children diagnosed with chronic, uncomplicated infections. These studies primarily focused on a specific outcome: the clearance of parasitic larvae, which researchers determined by monitoring for the absence of larvae in stool samples over time.

Comparative Trials and Confirmation of Clearance

This area of research examined how Euromec performed relative to other existing treatments for this infection. The research contributes to understanding symptom patterns by comparing the different measured outcomes. A key challenge was observed in the studies: confirming the complete absence of larvae is difficult. This means researchers often needed multiple stool examinations over several months to confidently assess whether clearance was maintained.

Evidence for Use in River Blindness (Onchocerciasis)

Research exploring Euromec’s use for River Blindness (onchocerciasis) involved Double-Blind, Placebo-Controlled Trials and large-scale community-based field trials conducted in areas where the disease is common. These studies monitored outcomes by measuring the density of Onchocerca volvulus microfilariae (larvae) in the skin and eyes. The study populations were adults and children living in these endemic regions, often evaluated as part of public health initiatives.

Research within Mass Drug Administration (MDA) Programs

This research was evaluated in entire communities where the medicine was observed in large groups of people over several years. These long-running studies examined outcomes reflecting daily functioning or activity level by measuring the overall reduction in parasite transmission rates at a population level. This evidence contributes to the broader evidence landscape by focusing on population-level metrics, such as reduced transmission rates.

Long-Term Studies and Follow-up Durability

For all indications, follow-up durations were limited in many of the initial trials. Studies explored short-term changes in measured outcomes, but data collection often stopped after a few weeks or months. For intestinal strongyloidiasis, for instance, long-term outcomes are not fully established, and it is uncertain whether parasitic clearance is sustained years after treatment.

Research Gaps and What Remains Uncertain

For strongyloidiasis, assessment of parasitic clearance requires consistent follow-up testing across studies, and evidence quality varies across studies regarding optimal testing protocols. Overall, for all anti-parasitic uses, long-term effects are not fully established, and the results apply only to the populations studied and the specific conditions under which the research was observed in. Research provides context but not individual predictions about a person's specific response.

Key Studies & References

  1. Guidelines for Stopping Mass Drug Administration and Verifying Elimination of Human Onchocerciasis (WHO)
  2. Ivermectin and permethrin for treating scabies (Cochrane Review)

Frequently Asked Questions (FAQ)

Common questions about Euromec (FAQ)


Q: What happens if I miss a dose of Euromec?

Euromec is most commonly administered as a single, curative dose, so the concept of a missed dose often does not apply. If a patient is following an intermittent schedule for long-term control, official guidance suggests taking the dose as soon as it is remembered in order to maintain the scheduled treatment program.

Q: Does Euromec interact with common pain relievers like ibuprofen?

Regulatory information does not specifically list common non-prescription pain relievers like ibuprofen as having a major known interaction with Euromec. However, official product labeling recommends that patients inform their healthcare provider or pharmacist about all concurrent medications and supplements, as interactions can occur.

Q: Can Euromec affect blood pressure readings?

Official safety data indicates that adverse events related to blood flow have been reported, such as orthostatic hypotension (a drop in blood pressure when standing up) and a rapid heart rate. It is important to be aware of these potential cardiovascular effects, particularly if a patient has a high parasitic burden.

Q: What are the signs that Euromec is actually working?

The effectiveness of Euromec is primarily measured clinically by confirmed clearance of parasites, which requires laboratory testing. However, for some infections, a reaction called the Mazzotti reaction (involving fever, itching, and rash) can occur shortly after treatment. This reaction is often considered a clinical manifestation that the medication is exerting its effect against the parasites.

Q: Do you have to take Euromec with food?

No. Official guidance strongly advises taking the medication on an empty stomach. This generally means taking it two hours before or two hours after eating a meal. This administration condition is recommended because taking it with food can significantly increase the drug's absorption, but taking it on an empty stomach helps optimize the drug's uptake.

Q: Is it true that Euromec can cause strange dreams?

The official safety profile reports a range of Nervous System Disorders and, in rare cases, serious neurological events like confusion or coma. While 'strange dreams' are not specifically listed, any unusual or significant change in sleep or mental status is a point of concern that should be raised with a healthcare professional.

Q: Why do some people say Euromec didn't work for them?

Official research acknowledges that confirming the complete clearance of parasites can be challenging, often requiring multiple follow-up tests over several months. Regulatory summaries state that research provides general context but cannot make individual predictions about a person's specific response to the medication. These factors contribute to why individual outcomes may not align with clinical trial averages.

Q: Can Euromec be crushed or split if someone has trouble swallowing pills?

For very young children, regulatory information explicitly states that the tablets may be crushed to help with swallowing. Adults or older patients experiencing difficulty swallowing typically need to consult a healthcare provider to confirm if crushing the tablet is an appropriate administration method for their specific case.

Q: Is Euromec the same type of drug as [common alternative]?

Euromec contains the active ingredient Ivermectin, which is classified as an anthelmintic and belongs to the macrocyclic lactone class. This classification defines its specific chemical structure and mechanism of action, distinguishing it from drugs in other classes used for similar conditions.

Q: Does taking Euromec make you tired or sleepy?

Official safety data lists dizziness as a common side effect. Furthermore, the label warns that if Euromec is used alongside other drugs that cause Central Nervous System (CNS) depression (such as certain anxiety medicines or alcohol), it could potentially increase the likelihood of effects such as drowsiness.

Q: How long does it typically take to feel the effects of Euromec?

While the exact time a patient perceives a change is not specified in regulatory documents, the drug's highest concentration in the blood is typically reached about four hours after taking the oral dose. The drug begins acting on the parasites immediately, though achieving complete clearance can take time.

Q: Can Euromec affect my mood or energy levels?

Official safety data reports possible effects on the central nervous system, including dizziness. Rarely, more serious neurological events such as confusion have been noted. Significant or persistent changes in mood or energy, if experienced, warrant contact with a healthcare provider.

Q: How long does Euromec stay in your system after stopping it?

Pharmacological data indicates that the drug's apparent plasma half-life is approximately 18 hours following oral administration. The active drug and its breakdown products are then slowly eliminated from the body, primarily through the feces, over an estimated period of about 12 days.

Q: Is there a generic version of Euromec available?

Yes. Euromec is a brand name for the active ingredient Ivermectin, which is widely available as a generic medication in the oral tablet form, in addition to specific brand-name products.

Q: Can Euromec cause stomach upset or digestive problems?

Yes, official safety documents list Gastrointestinal Disorders as a category where adverse reactions may occur. These commonly reported reactions include symptoms such as nausea, vomiting, diarrhea, constipation, and general abdominal pain.

Q: Are there specific times of the day recommended for taking Euromec?

Regulatory guidance focuses mainly on the condition of the stomach, recommending that the drug be taken on an empty stomach. There are no general regulatory guidelines recommending a specific time of day, such as morning or evening, over another.

Q: Are there any known interactions between Euromec and herbal supplements?

Yes, potential interactions exist. Official documents mandate informing a healthcare provider about all concurrent use of prescription medicines, over-the-counter drugs, and herbal products, as these substances can potentially alter the drug's effectiveness or safety.

Q: What age group is Euromec generally prescribed for?

Euromec is typically prescribed for adults and children. However, regulatory authorities state that safety and effectiveness have not been established in children weighing less than 15 kilograms (kg).

Q: Have there been any major studies on Euromec in the last few years?

Official regulatory summaries provide a basis for the drug's use based on foundational research, including randomized controlled trials and mass drug administration programs. These documents focus on studies confirming efficacy for its labeled uses, but they do not specifically list or summarize the findings of all recent research.

Q: Why do I feel slightly dizzy sometimes after taking Euromec?

Dizziness is listed in the official safety profile as a Common adverse effect, meaning it is reported in 1 in 100 people or more. A patient experiencing dizziness should use caution when performing activities that require concentration or standing up quickly.

Q: Are there any known issues with driving while taking Euromec?

Official safety data does not explicitly prohibit driving, but common side effects include dizziness. In rare cases, more serious neurological events like confusion have been reported. Any side effect that impairs concentration, coordination, or alertness could affect the ability to drive or operate machinery safely.

Q: How quickly can I expect Euromec to start its full therapeutic effect?

Euromec is designed to clear parasites from the body after a single dose, but the time to achieve the full therapeutic effect (i.e., confirmed parasite clearance) can vary significantly. Clinical studies on some conditions required follow-up testing over several months to confidently confirm sustained clearance.

Q: Can Euromec interact with common cold or flu medicines?

Yes, there is a potential for interaction. Regulatory documents warn that taking Euromec with other medications that cause Central Nervous System (CNS) depression could enhance side effects such as drowsiness or dizziness. Therefore, any use of such medicines alongside Euromec should be reviewed by a healthcare professional.

Q: Are there any serious warning signs to look out for when on Euromec?

Yes, there are serious, though rare, adverse reactions reported in official documents. Immediate medical attention is necessary if signs of severe skin reactions like Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN) are observed, or if severe neurological effects such as profound confusion occur.

How should Euromec be stored and disposed of?

To maintain the effectiveness and safety of your medication, store Euromec at room temperature, typically between 15 C and 30 C (or 59 F and 86 F). Always keep it in its original container and protect it from moisture and excessive heat. Do not store medication in a bathroom cabinet, as the heat and humidity can compromise its quality.

Critically, you must keep Euromec out of the reach and sight of children and pets to prevent accidental ingestion, ideally secured in a locked cabinet.

When disposing of expired or unused medication, do not flush Euromec down a toilet or pour it down a sink unless specifically instructed to do so by a healthcare professional or regulatory guideline. The safest method of disposal is through a local drug take-back program or by returning it to your community pharmacy. If no take-back program is available, you may be able to dispose of it in your household trash after mixing it with an unappealing substance like used coffee grounds or cat litter and sealing it in a plastic bag.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Euromec found in:

A-Z Index: